CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $14,851, lower than 95% of all stocks globally
- PositionOperating margin is -292397.9%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.52TKRW1.10B · vs all stocks (USD)
Revenue (TTM)
20.61MKRW14.85K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
213.78%vs all stocks
Market Capitalization
1.52TKRW1.10B · vs all stocks (USD)
Enterprise Value
1.44TKRW1.04B · vs all stocks (USD)
Price to Book (MRQ)
13.54xvs Biotechnology peers
Enterprise to EBITDA
-25.37xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-14.94%vs Biotechnology peers
Return on Equity (TTM)
-22.35%vs Biotechnology peers
Revenue (TTM)
20.61MKRW14.85K · vs all stocks (USD)
Revenue per Share (TTM)
0.9590KRWUpdated Aug 20, 2026Gross Profit (TTM)
20.18MKRW14.54K · vs all stocks (USD)
EBITDA (TTM)
-56.91BKRW-41.01M · vs all stocks (USD)
Net Income (TTM)
-48.65BKRW-35.05M · vs all stocks (USD)
Operating Cash Flow (TTM)
-44.02BKRW-31.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.92BKRW-19.40M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
23.56MKRWFY2025 · Dec 31, 2025Gross Profit
23.56MKRWFY2025 · Dec 31, 2025Operating Income
-51.76BKRW-37.30M · vs all stocks (USD)
Pre-tax Income
-44.15BKRWFY2025 · Dec 31, 2025Income Tax Expense
-2.18BKRWFY2025 · Dec 31, 2025Net Income
-41.97BKRWFY2025 · Dec 31, 2025EBIT
-42.27BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-41.87BKRWFY2025 · Dec 31, 2025Research & Development
35.65BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.86BKRWFY2025 · Dec 31, 2025Other Operating Expenses
269.96MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.88BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.97BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-44.87BKRWFY2025 · Dec 31, 2025Free Cash Flow
-45.56BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.07BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.97BKRWFY2025 · Dec 31, 2025Stock-based Compensation
867.79MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-3.74BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-73.11MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
52.39MKRWFY2025 · Dec 31, 2025Capital Expenditures
-696.27MKRWFY2025 · Dec 31, 2025Purchase of Investments
-97.63BKRWFY2025 · Dec 31, 2025Sale of Investments
70.00BKRWFY2025 · Dec 31, 2025Other Investing Activity
-20.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.32BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
49.57BKRWFY2025 · Dec 31, 2025Shares Outstanding
21.23MSharesUpdated Aug 20, 2026Float Shares
16.20MSharesUpdated Aug 20, 2026% Held by Insiders
15.84%vs all stocks
% Held by Institutions
9.98%vs all stocks
Total Cash (MRQ)
274.23BKRW197.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.15KKRWUpdated Aug 20, 2026Total Debt (MRQ)
26.61BKRW19.18M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0973xvs Biotechnology peers
Current Ratio (MRQ)
17.89xvs Biotechnology peers
Book Value per Share (MRQ)
5.30KKRWUpdated Aug 20, 2026Total Assets
169.32BKRW122.01M · vs all stocks (USD)
Total Current Assets
134.37BKRWFY2025 · Dec 31, 2025Total Liabilities
38.44BKRWFY2025 · Dec 31, 2025Total Non-current Assets
34.95BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
22.83BKRWFY2025 · Dec 31, 2025Total Current Liabilities
15.61BKRWFY2025 · Dec 31, 2025Cash Equivalents
4.07BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.07BKRWFY2025 · Dec 31, 2025Other Short-term Investments
128.54BKRWFY2025 · Dec 31, 2025Accounts Receivable
558.17KKRWFY2025 · Dec 31, 2025Short-term Debt
2.78BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-140.00KRWFY2025 · Dec 31, 2025Long-term Debt
22.72BKRWFY2025 · Dec 31, 2025Common Stock (Book)
2.12BKRWFY2025 · Dec 31, 2025Retained Earnings
18.22BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
130.89BKRW94.31M · vs all stocks (USD)
52-Week Low
22.65KKRWUpdated Aug 20, 202652-Week High
146.60KKRWUpdated Aug 20, 202652-Week Change
213.78%vs all stocks
50-Day MA
55.11KKRWUpdated Aug 20, 2026200-Day MA
83.70KKRWUpdated Aug 20, 2026Avg 10-Day Volume
161.71KSharesUpdated Aug 20, 2026Avg 30-Day Volume
118.27KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-2.02KKRWUpdated Aug 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -292397.9%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -2,923.979Industry median: -0.34Industry P5: -43.55Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $14,851, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,851.246Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Oddity Tech Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Shenzhen JDD Tech New Material Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Hangzhou XZB Tech Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated